Cited by 375Clinical Laboratory Practices and Quality ControlAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

Open access

Bittner, Tobias, Zetterberg, Henrik, Teunissen, Charlotte E., Ostlund, Richard E., Militello, Michael, Andreasson, Ulf, Hubeek, Isabelle, Gibson, David, Chu, David C., Eichenlaub, Udo, Heiss, Peter, Kobold, Uwe, Leinenbach, Andreas, Madin, Kairat, Manuilova, Ekaterina, Rabe, Christina, Blennow, Kaj·2016·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2015.09.009

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: Available assays for quantitation of the Alzheimer's disease (AD) biomarker amyloid-beta 1-42 (Aβ [1-42]) in cerebrospinal fluid demonstrate significant variability and lack of standardization to reference measurement procedures (RMPs). We report analytical performance data for the novel Elecsys β-amyloid (1-42) assay (Roche Diagnostics). METHODS: Lot-to-lot comparability was tested using method comparison. Performance parameters were measured according to Clinical & Laboratory Standards Institute (CLSI) guidelines. The assay was standardized to a Joint Committee for Traceability in Laboratory Medicine (JCTLM) approved RMP. RESULTS: Limit of quantitation was <11.28 pg/mL, and the assay was linear throughout the measuring range (200-1700 pg/mL). Excellent lot-to-lot comparability was observed (correlation coefficients [Pearson's r] >0.995; bias in medical decision area <2%). Repeatability coefficients of variation (CVs) were 1.0%-1.6%, intermediate CVs were 1.9%-4.0%, and intermodule CVs were 1.1%-3.9%. Estimated total reproducibility was 2.0%-5.1%. Correlation with the RMP was good (Pearson's r, 0.93). DISCUSSION: The Elecsys β-amyloid (1-42) assay has high analytical performance that may improve biomarker-based AD diagnosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2015.09.009

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I
Passing, H., & Bablok, W. (1983) · cclm · doi:10.1515/cclm.1983.21.11.709 · Cited by 1,513
Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 649

Show all 37 references

Research works printed but not linked: 8

Clinical Laboratory and Standards Institute (CLSI), 2012, Evaluation of detection capability for clinical laboratory measurement procedures: Approved guideline—Second edition. CLSI Document EP17–A2
Clinical Laboratory and Standards Institute (CLSI), 2003, Evaluation of the linearity of quantitative measurement procedures: A statistical approach; approved guideline. CLSI Document EP06‐A
Clinical Laboratory and Standards Institute (CLSI), 2013, Measurement procedure comparison and bias estimation using patient samples; approved guideline—Third edition. CLSI Document EP09–A3
Clinical Laboratory and Standards Institute (CLSI), 2005, Interference testing in clinical chemistry; approved guideline—Second edition. CLSI Document EP7–A2
Clinical Laboratory and Standards Institute (CLSI), 2008, Immunoassay interference by endogenous antibodies; approved guideline. CLSI Document I/LA30‐A
Clinical Laboratory and Standards Institute (CLSI), 2014, Evaluation of precision of quantitative measurement procedures; approved guideline—Third edition. CLSI Document EP05–A3
Clinical Laboratory and Standards Institute (CLSI), 2014, User verification of performance for precision and trueness; approved guideline—Second edition. CLSI Document EP15–A2
Scheltens P, 2014, Baseline patient characteristics from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD, J Prev Alzheimers Dis, 1, 231

Sorted by citations

Items 201–300 of 375

Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Results from the European Prevention of Alzheimer’s Dementia (EPAD) v500.0 Cohort
Watermeyer, T. J., Marroig, A., Ritchie, C. W., Ritchie, K. A., Blennow, K., & Terrera, G. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200514 · Cited by 12
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation
Klafki, H.-W., Vogelgsang, J. S., Manuilova, E., Bauer, C., Jethwa, A., Esselmann, H., Jahn‐Brodmann, A., Osterloh, D., Lachmann, I., Breitling, B., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01071-y · Cited by 14
Cerebrospinal fluid in the dementias
Zetterberg, H., Rohrer, J. D., & Schott, J. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00006-x · Cited by 13
A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
Brum, W. S., Bastiani, M. A. D., Bieger, A., Therriault, J., Ferrari‐Souza, J. P., Benedet, A. L., Saha‐Chaudhuri, P., Souza, D. O., Ashton, N. J., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12270 · Cited by 12
Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe
Miller, A.-M., Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. J., Winblad, B. G., Waldemar, G., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170502 · Cited by 12
Decreased brain interstitial fluid dynamics is associated with risk of Alzheimer’s disease-related cognitive decline
Guo, Y., Liu, T., Chen, H., Zhou, L., Huang, W., Zhang, K., Wang, X., wang, Y., Zhou, J. H., & Chen, F. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111295 · Cited by 13
Dissecting the clinical and pathological prognosis of MCI patients who reverted to normal cognition: a longitudinal study
Yu, H., Tan, L., Jiao, M.-J., Lv, Y.-J., Zhang, X.-H., Tan, C., Xu, W., & Initiative, A. D. N. (2025) · BMC Medicine · doi:10.1186/s12916-025-04092-0 · Cited by 15
The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer’s Disease Risks
Kim, H., Initiative, O. B. O. T. A. D. N., Levine, A., Cohen, D., Gehrman, P., Zhu, X., Devanand, D. P., Lee, S., & Goldberg, T. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215417 · Cited by 14
Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults
Dídac Vidal-piñeiro, A., Sørensen, Ø., Blennow, K., Capogna, E., Halaas, N. B., Idland, A., Mowinckel, A. M., Pereira, J. B., Watne, L. O., Zetterberg, H., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.04.010 · Cited by 11
Using LC-MS/MS to Determine Salivary Steroid Reference Intervals in a European Older Adult Population
Gregory, S., Denham, S. G., Lee, P. J., Simpson, J. P., & Homer, N. Z. M. (2023) · Metabolites · doi:10.3390/metabo13020265 · Cited by 10
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer’s disease
Gaetani, L., Chiasserini, D., Paoletti, F. P., Bellomo, G., & Parnetti, L. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2276918 · Cited by 10
MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
Wisse, L. E. M., Spotorno, N., Rossi, M., Grothe, M. J., Mammana, A., Tideman, P., Baiardi, S., Strandberg, O. T., Ticca, A., van Westen, D., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2713 · Cited by 10
Plasma phosphorylated tau181 outperforms [ 18F ] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease
Quispialaya, K. M., Therriault, J., Aliaga, A., Tissot, C., Servaes, S., Rahmouni, N., Karikari, T. K., Benedet, A. L., Ashton, N. J., Macedo, A. C., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16255 · Cited by 12
Microstructural white matter injury contributes to cognitive decline: Besides amyloid and tau
Hu, H., Li, H., Gong, W., Huang, S., Fu, Y., Hu, H., Dong, Q., Cheng, W., Tan, L., Cui, M., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100037 · Cited by 11
Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects
Somers, C., Lewczuk, P., Sieben, A., Broeckhoven, C. V., Deyn, P. P. D., Kornhuber, J., Martin, J., Bjerke, M., & Engelborghs, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180563 · Cited by 10
Associations Between Multimorbidity and Cerebrospinal Fluid Amyloid: A Cross-Sectional Analysis of the European Prevention of Alzheimer’s Dementia (EPAD) V500.0 Cohort
Stirland, L., Russ, T. C., Ritchie, C. W., & Terrera, G. M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190222 · Cited by 10
APOE-ε4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks
Cacciaglia, R., Molinuevo, J. L., Falcón, C., Arenaza‐Urquijo, E. M., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Blennow, K., Zetterberg, H., Gispert, J. D., study, F. T. A., et al. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa034 · Cited by 9
Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review
Avila-Vazquez, M., Altamirano-Bustamante, N. F., & Altamirano‐Bustamante, M. M. (2017) · Molecules · doi:10.3390/molecules23010079 · Cited by 10
miR-423-5p and miR-92a-3p in Alzheimer’s disease: relationship with pathology and cognition
Han, S., Park, Y. H., Pyun, J., Bice, P. J., Kim, S., Saykin, A. J., & Nho, K. T. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1637368 · Cited by 11
Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays
Schauer, S. P., Mylott, W. R., Jr., Yuan, M., Jenkins, R. G., Mathews, W. R., Honigberg, L. A., & Wildsmith, K. R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0445-0 · Cited by 9
Association of the fibronectin type III domain–containing protein 5 rs1746661 single nucleotide polymorphism with reduced brain glucose metabolism in elderly humans
Lima‐Filho, R. A. S., Benedet, A. L., Bastiani, M. A. D., Povala, G., Cozachenco, D., Ferreira, S. T., Felice, F. G. D., Rosa‐Neto, P., Zimmer, E. R., Lourenco, M. V., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad216 · Cited by 9
CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer’s disease
Qiang, Q., Skudder‐Hill, L., Toyota, T., Huang, Z., Wei, W., Adachi, H., & Initiative, A. D. N. (2023) · Brain Communications · doi:10.1093/braincomms/fcad312 · Cited by 9
CSF 14–3-3 zeta(ζ) isoform is associated with tau pathology and cognitive decline in Alzheimer's disease
Qiang, Q., Skudder‐Hill, L., Toyota, T., Huang, Z., Wei, W., & Adachi, H. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.122861 · Cited by 10
Alzheimer’s disease susceptibility locus in CD2AP is associated with increased cerebrospinal fluid tau levels in mild cognitive impairment
Xue, Y., Chen, Y.-H., Lin, R.-R., Huang, H.-F., Wu, Z., & Tao, Q. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136419 · Cited by 9
Categorical predictive and disease progression modeling in the early stage of Alzheimer’s disease
Platero, C. A. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2022.109581 · Cited by 8
Posttraumatic stress disorder symptom severity is associated with reduced Montreal Cognitive Assessment scores in a sample of Vietnam War Veterans
Prieto, S., Moody, J. N., Valerio, K. E., & Hayes, J. P. (2022) · Journal of Traumatic Stress · doi:10.1002/jts.22830 · Cited by 8
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment
Parnetti, L., & Eusebi, P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179910 · Cited by 8
The Diagnostic Potential of Amyloidogenic Proteins
Jin, Y., Vadukul, D. M., Gialama, D., Ge, Y., Thrush, R. J., White, J. T., & Aprile, F. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084128 · Cited by 9
Immunity gene IFITM3 variant: Relation to cognition and Alzheimer's disease pathology
Pyun, J., Park, Y. H., Hodges, A., Jang, J., Bice, P. J., Kim, S., Saykin, A. J., & Nho, K. T. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12317 · Cited by 7
CSF Biomarkers in Longitudinal Alzheimer Disease Cohorts: Pre-Analytic Challenges
Jonaitis, E. M., Jeffers, B., VandenLangenberg, M., Ma, Y., Hulle, C. V., Langhough, R. E., Du, L., Chin, N. A., Przybelski, R. J., Hogan, K. J., et al. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad221 · Cited by 8
Guidelines for the use and interpretation of Alzheimer’s disease biomarkers in clinical practice in Brazil: recommendations from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
Studart‐Neto, A., Barbosa, B. J. A. P., Coutinho, A. M., de Souza, L. C., Schilling, L. P., da Silva, M. N. M., Castilhos, R. M., Bertolucci, P. H. F., Borelli, W. V., Gomes, H. R., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c001 · Cited by 11
Automation on an Open-Access Platform of Alzheimer’s Disease Biomarker Immunoassays
Gille, B., Dedeene, L., Stoops, E., Demeyer, L., François, C., Lefever, S., Schaepdryver, M. D., Brix, B., Vandenberghe, R. R., Tournoy, J., et al. (2018) · SLAS TECHNOLOGY · doi:10.1177/2472630317750378 · Cited by 8
Genome-Wide Association Study Identifies SLAMF1 Affecting the Rate of Memory Decline
Chen, S.-D., Initiative, O. B. O. A. D. N., Li, H., Shen, X., Li, J., Xu, W., Huang, Y., Tan, L., Dong, Q., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191214 · Cited by 8
BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
Kim, J. P., Kim, B.-H., Bice, P. J., Seo, S. W., Bennett, D. A., Saykin, A. J., Nho, K. T., & Initiative, A. D. N. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00906-4 · Cited by 7
Soluble TREM2, Alzheimer’s Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study
Wu, C., Initiative, A. D. N., Ma, Y., Hu, H., Zhao, B. T., & Tan, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220731 · Cited by 8
Characterizing the clinical heterogeneity of early symptomatic Alzheimer’s disease: a data-driven machine learning approach
Wang, X., Ye, T., Jiang, D., Zhou, W., Zhang, J., & Initiative, A. D. N. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1410544 · Cited by 7
Neuroimaging-derived biological brain age and its associations with glial reactivity and synaptic dysfunction cerebrospinal fluid biomarkers
Cumplido‐Mayoral, I., Sánchez‐Benavides, G., Vilor‐Tejedor, N., López‐Martos, D., Brugulat‐Serrat, A., Milà‐Alomà, M., Falcón, C., Cacciaglia, R., Minguillón, C., Fauria, K., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02961-x · Cited by 9
AI-based staging, causal hypothesis and progression of subjects at risk of Alzheimer’s disease: a multicenter study
Aresta, S., Nemni, R., Zanardo, M., Sirabian, G., Capelli, D., Alì, M., Vitali, P., Bertoldo, E. G., Fiolo, V., Bonanno, L., et al. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1568086 · Cited by 7
Alzheimer disease biomarkers are associated with decline in subjective memory, attention, and spatial navigation ability in clinically normal adults
Levine, T. F., Dessenberger, S. J., Allison, S. L., Head, D. M., & Initiative, T. A. D. N. (2023) · Journal of the International Neuropsychological Society · doi:10.1017/s135561772300070x · Cited by 7
Uptake of 18F-AV45 in the Putamen Provides Additional Insights into Alzheimer’s Disease beyond the Cortex
Yang, Z., Kinney, J. W., Cordes, D., & Initiative, T. A. D. N. (2024) · Biomolecules · doi:10.3390/biom14020157 · Cited by 7
Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid-β peptides 1–42 and 1–40 in CSF
Forgrave, L. M., van der Gugten, J. G., Nguyen, Q., & DeMarco, M. L. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0549 · Cited by 8
Diagnostic Cut-offs for CSF β-amyloid and tau proteins in a Danish dementia clinic
Abildgaard, A. M., Parkner, T., Knudsen, C. S., Gottrup, H., & Klit, H. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.12.023 · Cited by 7
Comparison of commonly measured plasma and cerebrospinal fluid proteins and their significance for the characterization of cognitive impairment status
Rehman, H., Initiative, F. T. A. D. N., Ang, T. F. A., Tao, Q., Espenilla, A. L., Au, R., Farrer, L. A., Zhang, X., & Qiu, W. Q. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-230837 · Cited by 7
Comparative analysis of Elecsys and ELISA for differentiating amyloid-PET status in a Korean memory clinic based on cerebrospinal fluid biomarkers
Park, S. A., An, Y., Park, Y.-J., Lee, J.-Y., Jeon, H., Kim, Y. S., Lee, K., Sun, K., Lee, S. M., & Moon, S. Y. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251314886 · Cited by 6
The CCL2 rs4586 SNP Is Associated with Slower Amyloid-β Deposition and Faster Tau Accumulation of Alzheimer’s Disease
Gao, F., Initiative, A. D. N., Zhang, P., Gao, J., Song, J., & Chi, S. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220716 · Cited by 7
Stratifying risk of Alzheimer’s disease in healthy middle-aged individuals with machine learning
Tandon, R., Zhao, L., Watson, C. M., Sarkar, N., Elmor, M. B., Heilman, C. J., Sanders, K., Hales, C. M., Yang, H., Loring, D. W., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf121 · Cited by 6
The association between pulse wave velocity and cerebrospinal fluid biomarkers for Alzheimer's disease
Kim, H., Kulshreshtha, A., Alonso, Á., Goldstein, F. C., Johnson, E. C. B., Gold, M. E., Quyyumi, A. A., & Lah, J. J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331235 · Cited by 6
Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers
Arenaza‐Urquijo, E. M., Salvadó, G., Operto, G., Minguillón, C., Sánchez‐Benavides, G., Crous‐Bou, M., Grau‐Rivera, O., Sala‐Vila, A., Falcón, C., Suárez‐Calvet, M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010527 · Cited by 6
Genome-Wide Association Study of Brain Alzheimer’s Disease-Related Metabolic Decline as Measured by [18F] FDG-PET Imaging
Wang, R., Initiative, A. D. N., Yang, Y., Li, H., Shen, X., Chen, S.-D., Dong, Q., Wang, Y., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200415 · Cited by 6
Resilience to Plasma and Cerebrospinal Fluid Amyloid-β in Cognitively Normal Individuals: Findings From Two Cohort Studies
Lin, L., Sun, Y., Wang, X., Su, L., Wang, X.-N., & Han, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.610755 · Cited by 6
Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer’s Disease and Vascular Pathology
Shir, D., Mielke, M. M., Hofrenning, E. I., Lesnick, T. G., Knopman, D. S., Petersen, R. C., Jack, C. R., Algeciras‐Schimnich, A., Vemuri, P., & Graff‐Radford, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221015 · Cited by 6
Amyloid‐β but not tau accumulation is strongly associated with longitudinal cognitive decline
Wang, W., Huang, J., Qian, S., Zheng, Y., Yu, X., Jiang, T., Ai, R., Hou, J., Ma, E., Cai, J., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14860 · Cited by 5
Plasma neurofilament light reflects more severe manifestation of Alzheimer’s disease in men
Cheng, X., Wang, Z., He, K., Xia, Y., Wang, Y., Guo, Q., Xie, F., & Yuan, P. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03149-z · Cited by 5
Neuropathologic correlates of cognitive impairment in Alzheimer’s disease with discordant CSF biomarker profiles: co-pathologies in focus
Ioannou, K., Perrin, R. J., Abdullaieva, K., Blūma, M., Leuzy, A., Poulakis, K., Religa, D., Rodriguez‐Vieitez, E., Chiotis, K., & Initiative, A. D. N. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02960-w · Cited by 5
Longitudinal cognitive change and duration of Alzheimer’s disease stages in relation to cognitive reserve
Li, L., Ni, L., Wang, X., & Sheng, C. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.09.017 · Cited by 5
Cerebrospinal Fluid Complement 4 Levels Were Associated with Alzheimer’s Disease Pathology and Cognition in Non-Demented Elderly
Zhou, J., Wang, Z., Sun, Y., Fu, Y., Li, D., Tan, L., & Initiative, A. D. N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230513 · Cited by 5
Lower Prevalence of Asymptomatic Alzheimer's Disease Among Healthy African Americans
Lah, J. J., Tian, G., Risk, B. B., Hanfelt, J., Wang, L., Zhao, L., Hales, C. M., Johnson, E. C. B., Elmor, M. B., Malakauskas, S., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26960 · Cited by 5
Cerebrospinal fluid neuronal pentraxin levels are associated with tau pathology via microglia–astrocyte signaling in alzheimer’s disease
Zhang, Z.-H., Chen, X., Sheng, Z.-H., Jiang, N., & Zou, W. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03545-w · Cited by 7
Metabolic alteration in oxylipins and endocannabinoids point to an important role for soluble epoxide hydrolase and inflammation in Alzheimer’s disease—finding from Alzheimer’s Disease Neuroimaging Initiative
Borkowski, K., Yin, C., Kindt, A., Liang, N., de Lange, E. C. M., Blach, C., Newman, J. W. I., Kaddurah‐Daouk, R., Hankemeier, T., & Initiative, T. F. L. D. N. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01939-9 · Cited by 9
Multiplexing of Immune Markers via Electrochemiluminescence Immunoassays for Systems Biology
Abhyankar, V. P., & Abidi, A. H. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0389-5_20 · Cited by 5
Concordance of Alzheimer’s Disease-Related Biomarkers Between Intraventricular and Lumbar Cerebrospinal Fluid in Idiopathic Normal Pressure Hydrocephalus
Lukkarinen, H., Vanninen, A., Tesseur, I. C., Pemberton, D. J., van der Ark, P. D., Kokkola, T., Herukka, S., Rauramaa, T. H., Hiltunen, M. O., Blennow, K., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220652 · Cited by 5
Clinical utility of self- and informant-reported memory, attention, and spatial navigation in detecting biomarkers associated with Alzheimer disease in clinically normal adults
Levine, T. F., Allison, S. L., Dessenberger, S. J., Head, D. M., & Initiative, A. D. N. (2023) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617723000528 · Cited by 6
Omega‐3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia
Lázaro, I., Grau‐Rivera, O., Suárez‐Calvet, M., Fauria, K., Minguillón, C., Shekari, M., Falcón, C., García-Prat, M., Huguet, J., Molinuevo, J. L., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12596 · Cited by 5
The Role of Sleep Apnea in Postoperative Neurocognitive Disorders Among Older Noncardiac Surgery Patients: A Prospective Cohort Study
Devinney, M. J., Spector, A. R., Wright, M. C., Thomas, J. P., Avasarala, P., Moretti, E. W., Dominguez, J. E., Smith, P. J., Whitson, H. E., Veasey, S. C., et al. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007269 · Cited by 5
Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum
Nilsson, N., Picard, C., Labonté, A., Köbe, T., Meyer, P., Villeneuve, S., Auld, D. S., Poirier, J., & Initiative, A. D. N. (2021) · Genes · doi:10.3390/genes12111805 · Cited by 5
Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone
Yosypyshyn, D., Kučikienė, D., Ramakers, I. H. G. B., Schulz, J. B., Initiative, A. D. N., Reetz, K., & Costa, A. S. (2023) · Neurological Research and Practice · doi:10.1186/s42466-023-00262-8 · Cited by 5
The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?
Fenouil, T., Fourier, A., Quadrio, I., Streichenberger, N., Bernardini, S., Zima, T., Perret‐Liaudet, A., & Meyronet, D. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.06.004 · Cited by 5
A limbic-predominant amnestic neurodegenerative syndrome associated with TDP-43 pathologyPreprint
Corriveau‐Lecavalier, N., Botha, H., Graff‐Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., et al. (2023) · medRxiv · doi:10.1101/2023.11.19.23298314 · Cited by 5
Frailty increases the risk of Alzheimer's disease in non-demented individuals: A longitudinal cohort study
Sheng, Z.-H., Liu, J.-Y., Ma, J., Mi, Y., Wang, H., Guo, F., Ma, L., Tan, L., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309081 · Cited by 5
APOE ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals
Woo, M. S., Macedo, A. C., Hosseini, S. A., Therriault, J., Wang, Y., Rahmouni, N., Aumont, É., Servaes, S., Tissot, C., Arias, J. F., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71048 · Cited by 4
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease
Lee, Y., Jeong, S. H., Park, M.-C., Kang, S. W., Baik, K., Jeon, S., Lee, P. H., Sohn, Y. H., & Ye, B. S. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00317-8 · Cited by 4
Visual Functions Are Associated with Biomarker Changes in Alzheimer’s Disease
Memon, A., Initiative, A. D. N., Moore, J. A., Kang, C., Ismail, Z., & Forkert, N. D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231084 · Cited by 4
A prediction model of dementia conversion for mild cognitive impairment by combining plasma pTau181 and structural imaging features
Li, T., Li, B.-L., Zhong, J., Xu, X., Wang, T., Liu, F., & Initiative, A. D. N. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70051 · Cited by 6
Axonal damage and inflammation response are biological correlates of decline in small-world values: a cohort study in autosomal dominant Alzheimer’s disease
Vermunt, L., Sutphen, C. L., Dicks, E., de Leeuw, D. M., Allegri, R., Berman, S., Cash, D. M., Chhatwal, J. P., Cruchaga, C., Day, G. S., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae357 · Cited by 6
Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease: Current and Future Application
Yang, J., Jia, L., Li, Y., Qiu, Q., Quan, M., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201068 · Cited by 4
Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study
Gregory, S., Blennow, K., Homer, N. Z. M., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15821 · Cited by 3
Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
Ma, Y., Norton, D., Hulle, C. A. V., Chappell, R. J., Lazar, K. K., Jonaitis, E. M., Koscik, R. L., Clark, L. R., Krause, R. A., Andréasson, U., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12194 · Cited by 3
Predictors of Cognitive Decline in Healthy Middle-Aged Individuals with Asymptomatic Alzheimer’s DiseasePreprint
Lah, J. J., Tandon, R., Zhao, L., Watson, C. M., Elmor, M. B., Heilman, C. J., Sanders, K., Hales, C. M., Yang, H., Loring, D. W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2577025/v1 · Cited by 4
Non-linear associations of amyloid-β with resting-state functional networks and their cognitive relevance in a large community-based cohort of cognitively normal older adults
Wu, J., Risk, B. B., James, T., Seyfried, N. T., Loring, D. W., Goldstein, F. C., Levey, A. I., Lah, J. J., & Qiu, D. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01986-w · Cited by 3
Traumatic Brain Injury and Genetic Risk for Alzheimer’s Disease Impact Cerebrospinal Fluid β-Amyloid Levels in Vietnam War Veterans
Moody, J. N., Howard, E., Nolan, K. E., Prieto, S., Logue, M. W., Hayes, J. P., & Initiative, A. D. N. (2024) · Neurotrauma Reports · doi:10.1089/neur.2024.0048 · Cited by 2
A family of estimators to diagnostic accuracy when candidate tests are subject to detection limits—Application to diagnosing early stage Alzheimer disease
Xiong, C., Luo, J., Agboola, F., Grant, E., & Morris, J. C. (2022) · Statistical Methods in Medical Research · doi:10.1177/09622802211072511 · Cited by 3
CSF α-synuclein aggregation is associated with APOE ε4 and progressive cognitive decline in Alzheimer's disease
Qiang, Q., Skudder‐Hill, L., Toyota, T., Huang, Z., Wei, W., & Adachi, H. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.02.008 · Cited by 3
The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ε4 genotypePreprint
Arnold, M., Nho, K. T., Kueider-Paisley, A., Massaro, T., Brauner, B., MahmoudianDehkordi, S., Louie, G., Moseley, M. A., Thompson, J. W., Williams, L. S. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/585455 · Cited by 4
Red blood cell ω-3 status and longitudinal cognition in individuals at risk of Alzheimer disease
Lázaro, I., Brugulat‐Serrat, A., Suárez‐Calvet, M., Fauria, K., Minguillón, C., Gispert, J. D., Molinuevo, J. L., Harris, W. S., Sánchez‐Benavides, G., Grau‐Rivera, O., et al. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.09.032 · Cited by 2
Exploring Alzheimer’s diseases with focus on diagnostic strategies targeting amyloid beta 42 (Aβ42)
Chauhan, A., Devi, R., Singh, S., Bhutani, K., Prasad, S., Singh, A., Bhaskar, N., Kumar, S., Saini, A. K., & Thakur, R. (2025) · Discover Neuroscience · doi:10.1186/s13064-025-00217-6 · Cited by 5
Proteins Associated with Cognition in Amyloid-beta Positive Elders Based on Cerebrospinal Fluid Proteomics
Liu, M., Hu, H., Fu, Y., Chi, H., Huang, L.-Y., Tan, L., & Hu, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05442-y · Cited by 2
Hippocampus-centered structural covariance network reorganization in Alzheimer’s disease: An individualized graph-based biomarker validated by machine learning
Lu, W., Gong, Q., Chen, Y., Qiu, S., & An, J. (2026) · Neural Networks · doi:10.1016/j.neunet.2026.108542 · Cited by 2
Diagnostic and prognostic utility of serum β-synuclein in Alzheimer’s disease: a longitudinal cohort study
Xie, S., Liang, Y., Yang, T., Sheng, D., Ding, L., & Jia, J. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100514 · Cited by 2
Estimating Dementia Onset: AT(N) Profiles and Predictive Modeling in Mild Cognitive Impairment Patients
Platero, C. A., Tohka, J., & Strange, B. A. (2023) · Current Alzheimer Research · doi:10.2174/0115672050295317240223162312 · Cited by 2
Association of CSF soluble TREM1 levels with hippocampal atrophy in cognitively impaired older adults
Shu, H., Ding, G., Xu, X., Huang, X., & He, R. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1481526 · Cited by 2
Association of cerebrospinal fluid ciliary neurotrophic factor levels with cognitive decline and disease progression
Wang, S., Han, L., Ni, H., Ke, S., Pan, T., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329612 · Cited by 2
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: A Canadian prospective
Kumar, P., Mousavi, A., & Frykman, H. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110980 · Cited by 2
Glia inflammation and cell death pathways drive disease progression in preclinical and early AD
Woo, M. S., Therriault, J., Hosseini, S. A., Wang, Y.-T., Macedo, A. C., Rahmouni, N., Aumont, É., Servaes, S., Tissot, C., Arias, J. F., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00316-1 · Cited by 5
Distinct effects of amyloid and tau deposition on eigenvector centrality during hippocampal down-regulation: a real-time fMRI virtual reality closed-loop neurofeedback study with CSF biomarkersPreprint
Skouras, S., Torner, J., Andersson, P., Koush, Y., Falcón, C., Minguillón, C., Fauria, K., Alpiste, F., Blenow, K., Zetterberg, H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/654426 · Cited by 1
A seven-year longitudinal study of the Alzheimer’s disease blood metabolomePreprint
Marella, B., Weinisch, P., Bless, J. J., Risacher, S. L., Blach, C., Karu, N., Kalecký, K., Wang, T., Huynh, K., Kueider‐Paisley, A., et al. (2025) · medRxiv · doi:10.64898/2025.12.05.25341709 · Cited by 3
The association of blood-based biomarkers of neuropathology with cognitive performance and incident dementia in a diverse, nationally-representative sample of US adultsPreprint
Faul, J. D., Crimmins, E. M., Kim, J. K., Thyagarajan, B., King, J. W., Weir, D. R., & Langa, K. M. (2026) · medRxiv · doi:10.64898/2026.01.07.26343604 · Cited by 2
Amyloid-β positivity is less prevalent in cognitively unimpaired KLOTHO KL-VS heterozygotes
Cook, N., Driscoll, I. F., Gaitán, J. M., Glittenberg, M., Betthauser, T. J., Carlsson, C. M., Johnson, S. C., Asthana, S., Zetterberg, H., Blennow, K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289785 · Cited by 2
Method comparison and re-calibration of three top-used immunoassays and one LC-MS/MS assay for four core cerebrospinal fluid biomarkers of Alzheimer’s disease: an explorative study for harmonization
Zou, Y., Ma, X., Mao, C., Chu, S., Wang, T., Jin, W., Wang, Y., Yu, S., Gao, J., & Qiu, L. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120352 · Cited by 1
Transfer learning reveals the mediating mechanisms of cross-ethnic lipid metabolic pathways in the association between APOE gene and Alzheimer’s disease
Pan, L., Liu, Y., Huang, C., Lin, R., Yu, Y., & Qin, G. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf460 · Cited by 1
Hypertension acts together with Aβ pathology in late-life to promote memory loss
Ros, L. U. D., Ferrari‐Souza, J. P., Bastiani, M. A. D., Hauschild, L. A., Bellaver, B., Ferreira, P. C. L., Leffa, D. T., Povala, G., Lussier, F. Z., Chamoun, M., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100579 · Cited by 1

Authors: Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., Heiss, P., Kobold, U., Leinenbach, A., Madin, K., Manuilova, E., Rabe, C., & Blennow, K.
Affiliations: Roche Diagnostics GmbH Penzberg Germany
UCL Queen Square Institute of Neurology (GB)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Washington University in St. Louis (US)
Covance (United States) (US)
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology The Sahlgrenska Academy at University of Gothenburg Mölndal Sweden
University of Gothenburg (SE)
Corresponding author: Blennow, Kaj
ORCID: Bittner, Tobias
Zetterberg, Henrik
Teunissen, Charlotte E.
Kobold, Uwe
Blennow, Kaj
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2015-11-07
Volume: 12
Issue: 5
Pages: 517-526
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2015.09.009
OpenAlex: W2111951761
Cited by: 374
References: 37
Citations by year: 2026: 27 · 2025: 41 · 2024: 49 · 2023: 29 · 2022: 35 · 2021: 52 · 2020: 41 · 2019: 39 · 2018: 33 · 2017: 15 · 2016: 11
FWCI: 14.49
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
Pure Amsterdam UMC (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Roche Diagnostics GmbH
Torsten Söderberg Foundation
Topics: Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: amyloid-beta 42, cerebrospinal fluid
MeSH terms: Alzheimer Disease, Humans, Immunoassay, Peptide Fragments, Reference Standards, Reproducibility of Results, Biomarkers, Amyloid beta-Peptides, Luminescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks